GleanMark

RYQOVRID Trademark

RYQOVRID is a USPTO trademark filed by Pfizer Inc.. Status: Pending.

Prosecution Summary

Trademark Summary
The standard character mark RYQOVRID covers pharmaceuticals in International Class 005, including preparations for treating autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders, as well as blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity, diabetes, anti-infectives, medicated dermatologicals, antifungals, smoking cessation preparations, and vaccines; it also spans Domestic Classes 006, 018, 044, 046, 051, and 052. The application is currently published for opposition, with t

Trademark Facts

MarkRYQOVRID
Serial Number99405371
StatusPending
Filing Date2025-09-22
Mark TypeWord
Nice Classes005 (Pharmaceuticals)
OwnerPfizer Inc.
Attorney of RecordYana Gorbach
Prosecution Events13
Latest EventNOAM on 2026-03-31

Goods & Services

Class 005: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, hormonal disorders, skin disorders, arthritis, cancer, cachexia, hypertension, migraine, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Antifungal preparations; Smoking cessation preparations; Vaccines for human use

Related